questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Sirtuines
Sirtuine-1
Sirtuine-1 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Complement C3-C5 Convertases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sirtuine-1 : Questions médicales les plus fréquentes",
"headline": "Sirtuine-1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sirtuine-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-13",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sirtuine-1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sirtuines",
"url": "https://questionsmedicales.fr/mesh/D037761",
"about": {
"@type": "MedicalCondition",
"name": "Sirtuines",
"code": {
"@type": "MedicalCode",
"code": "D037761",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.900"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sirtuine-1",
"alternateName": "Sirtuin 1",
"code": {
"@type": "MedicalCode",
"code": "D056564",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Giulia Bononi",
"url": "https://questionsmedicales.fr/author/Giulia%20Bononi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Valentina Citi",
"url": "https://questionsmedicales.fr/author/Valentina%20Citi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Alma Martelli",
"url": "https://questionsmedicales.fr/author/Alma%20Martelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Giulio Poli",
"url": "https://questionsmedicales.fr/author/Giulio%20Poli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Tiziano Tuccinardi",
"url": "https://questionsmedicales.fr/author/Tiziano%20Tuccinardi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.",
"datePublished": "2024-05-06",
"url": "https://questionsmedicales.fr/article/38709564",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1681/ASN.0000000000000373"
}
},
{
"@type": "ScholarlyArticle",
"name": "C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease.",
"datePublished": "2022-06-23",
"url": "https://questionsmedicales.fr/article/35734939",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ajmg.c.31986"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of Serum Complement C3 Levels with Severity and Mortality in COVID 19.",
"datePublished": "2023-08-16",
"url": "https://questionsmedicales.fr/article/37746543",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12291-023-01148-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.",
"datePublished": "2024-08-12",
"url": "https://questionsmedicales.fr/article/39133885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/NXI.0000000000200293"
}
},
{
"@type": "ScholarlyArticle",
"name": "GalNAc-Conjugated siRNA Targeting Complement C3 Inhibits Osteoclast Activation in Periodontitis.",
"datePublished": "2024-10-29",
"url": "https://questionsmedicales.fr/article/39472674",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/odi.15170"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sirtuines",
"item": "https://questionsmedicales.fr/mesh/D037761"
},
{
"@type": "ListItem",
"position": 6,
"name": "Sirtuine-1",
"item": "https://questionsmedicales.fr/mesh/D056564"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sirtuine-1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sirtuine-1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sirtuine-1",
"description": "Comment évaluer le niveau de Sirtuine-1 ?\nQuels tests sont utilisés pour la Sirtuine-1 ?\nY a-t-il des biomarqueurs associés à Sirtuine-1 ?\nLa génétique influence-t-elle Sirtuine-1 ?\nPeut-on mesurer Sirtuine-1 dans les tissus ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sirtuine-1",
"description": "Quels symptômes sont liés à une faible Sirtuine-1 ?\nLa Sirtuine-1 affecte-t-elle le vieillissement ?\nQuels effets sur la santé mentale ?\nY a-t-il des symptômes de maladies liées à Sirtuine-1 ?\nSirtuine-1 influence-t-elle l'énergie cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sirtuine-1",
"description": "Comment prévenir la baisse de Sirtuine-1 ?\nLe stress affecte-t-il Sirtuine-1 ?\nY a-t-il des habitudes à éviter ?\nLe sommeil influence-t-il Sirtuine-1 ?\nDes suppléments pour Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sirtuine-1",
"description": "Quels traitements augmentent Sirtuine-1 ?\nY a-t-il des médicaments ciblant Sirtuine-1 ?\nComment la nutrition affecte-t-elle Sirtuine-1 ?\nL'exercice physique influence-t-il Sirtuine-1 ?\nDes thérapies géniques pour Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sirtuine-1",
"description": "Quelles complications sont liées à une faible Sirtuine-1 ?\nSirtuine-1 et maladies cardiovasculaires ?\nY a-t-il un lien avec le diabète ?\nSirtuine-1 et cancer ?\nComplications neurologiques liées à Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sirtuine-1",
"description": "Quels facteurs augmentent le risque de faible Sirtuine-1 ?\nL'alimentation influence-t-elle Sirtuine-1 ?\nLe mode de vie sédentaire affecte-t-il Sirtuine-1 ?\nLe tabagisme impacte-t-il Sirtuine-1 ?\nLe stress oxydatif influence-t-il Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer le niveau de Sirtuine-1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le niveau de Sirtuine-1 peut être mesuré par des tests sanguins ou des biopsies tissulaires."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la Sirtuine-1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des analyses protéomiques sont utilisés pour évaluer Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à Sirtuine-1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biomarqueurs comme les niveaux de NAD+ peuvent être associés à Sirtuine-1."
}
},
{
"@type": "Question",
"name": "La génétique influence-t-elle Sirtuine-1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent affecter l'expression de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer Sirtuine-1 dans les tissus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Sirtuine-1 peut être mesurée dans des échantillons de tissus par immunohistochimie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une faible Sirtuine-1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible Sirtuine-1 peut être associée à des troubles métaboliques et à l'inflammation."
}
},
{
"@type": "Question",
"name": "La Sirtuine-1 affecte-t-elle le vieillissement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Sirtuine-1 est impliquée dans la régulation du vieillissement cellulaire et de la longévité."
}
},
{
"@type": "Question",
"name": "Quels effets sur la santé mentale ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de Sirtuine-1 peuvent influencer l'humeur et la cognition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes de maladies liées à Sirtuine-1 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète et les maladies neurodégénératives sont liées à Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Sirtuine-1 influence-t-elle l'énergie cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Sirtuine-1 joue un rôle clé dans la régulation de l'énergie cellulaire et du métabolisme."
}
},
{
"@type": "Question",
"name": "Comment prévenir la baisse de Sirtuine-1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain avec une bonne nutrition et de l'exercice aide à prévenir la baisse."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il Sirtuine-1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut réduire l'expression de Sirtuine-1 dans les cellules."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en sucres peut aider à maintenir Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Le sommeil influence-t-il Sirtuine-1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sommeil de qualité est essentiel pour maintenir des niveaux optimaux de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Des suppléments pour Sirtuine-1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments comme le resvératrol peuvent être bénéfiques pour soutenir Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Quels traitements augmentent Sirtuine-1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme le resvératrol et l'exercice physique peuvent augmenter Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments ciblant Sirtuine-1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments expérimentaux visent à moduler l'activité de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Comment la nutrition affecte-t-elle Sirtuine-1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en polyphénols peut stimuler l'expression de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il Sirtuine-1 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier est connu pour augmenter les niveaux de Sirtuine-1 dans le corps."
}
},
{
"@type": "Question",
"name": "Des thérapies géniques pour Sirtuine-1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour moduler Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une faible Sirtuine-1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible Sirtuine-1 est liée à des maladies métaboliques et à des troubles neurodégénératifs."
}
},
{
"@type": "Question",
"name": "Sirtuine-1 et maladies cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux bas de Sirtuine-1 peuvent augmenter le risque de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une faible Sirtuine-1 est associée à une résistance à l'insuline et au diabète de type 2."
}
},
{
"@type": "Question",
"name": "Sirtuine-1 et cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que Sirtuine-1 pourrait jouer un rôle dans la progression de certains cancers."
}
},
{
"@type": "Question",
"name": "Complications neurologiques liées à Sirtuine-1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une dysrégulation de Sirtuine-1 est liée à des maladies comme Alzheimer et Parkinson."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de faible Sirtuine-1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le vieillissement et le stress chronique augmentent le risque de faible Sirtuine-1."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Sirtuine-1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation pauvre en nutriments peut réduire l'expression de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire affecte-t-il Sirtuine-1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire est un facteur de risque pour une faible Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Le tabagisme impacte-t-il Sirtuine-1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à une diminution des niveaux de Sirtuine-1 dans l'organisme."
}
},
{
"@type": "Question",
"name": "Le stress oxydatif influence-t-il Sirtuine-1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut réduire l'activité de Sirtuine-1 et affecter la santé cellulaire."
}
}
]
}
]
}
C3 glomerulopathy is a rare disease resulting from an overactivation of the complement alternative pathway. Although there is also evidence of terminal pathway activation, its occurrence and consequen...
We retrospectively studied a cohort of 42 patients diagnosed with C3 glomerulopathy. We performed centralized extensive characterization of histological parameters. Kidney C5b-9 staining was performed...
Eighty-eight percent of biopsies showed C5b-9 deposits in glomeruli. Biopsies were grouped according to the amount of C5b-9 deposits (no or low n=15/42, 36%, intermediate n=15/42, 36%, and high n=12/4...
In a cohort of patients with C3 glomerulopathy, intra-renal terminal pathway activation was associated with specific histological phenotype and disease prognosis....
C3 glomerulopathy (C3G) describes a pathologic pattern of injury diagnosed by renal biopsy. It is characterized by the dominant deposition of the third component of complement (C3) in the renal glomer...
The severe acute respiratory distress syndrome-associated coronavirus-2 infection can activate innate and adaptive immune responses which may lead to harmful tissue damage, both locally and systemical...
The online version contains supplementary material available at 10.1007/s12291-023-01148-x....
In myelin oligodendrocyte glycoprotein IgG-associated disease (MOGAD) and aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (AQP4+NMOSD), the autoantibodies are mainly composed of IgG1, and comp...
CSF-C3a, CSF-C4a, CSF-C5a, and CSF-C5b-9 levels during the acute phase before treatment in patients with MOGAD (n = 12), AQP4+NMOSD (n = 11), multiple sclerosis (MS) (n = 5), and noninflammatory neuro...
CSF-C3a and CSF-C5a levels were significantly higher in MOGAD (mean ± SD, 5,629 ± 1,079 pg/mL and 2,930 ± 435.8 pg/mL) and AQP4+NMOSD (6,017 ± 3,937 pg/mL and 2,544 ± 1,231 pg/mL) than in MS (1,507 ± ...
The complement pathway is activated in both MOGAD and AQP4+NMOSD, but MAC formation is lower in MOGAD, particularly in those with mild attacks, than in AQP4+NMOSD. These findings may have pathogenetic...
The complement cascade plays an important role in the inflammation amplification and tissue destruction of periodontitis. Importantly, complement C3 was proved to be the central element of complement ...
The siRNAs targeting C3 were designed and screened for in vitro potency. The selected siRNA was conjugated to GalNAc (GalNAc-C3 siRNA) for liver-specific delivery. The mouse model of periodontitis was...
GalNAc-C3 siRNA showed great in vivo potency and durability to silence hepatic C3 mRNA expression. GalNAc-C3 siRNA treatment could effectively inhibit the production of inflammatory cytokines (IL-17A,...
GalNAc-C3 siRNA could efficiently play a role in bone protection by inhibiting inflammatory responses and osteoclast activities. This therapeutic siRNA may become an effective treatment strategy for p...
IgA nephropathy is the most common primary GN worldwide, with dominant deposition of IgA and co-deposits of complement component 3 (C3). Phenotypes and progression of IgA nephropathy varies among diff...
To further explore the effect of rs6677604 on IgA nephropathy progression, here we enrolled a Chinese IgA nephropathy cohort of 1781 patients with regular follow-up for analysis. The rs6677604 genotyp...
We found that patients with rs6677604-GG genotype had a stronger intensity of mesangial C3 deposition than those with the rs6677604-AA/AG genotype. Patients with IgA nephropathy who had stronger inten...
We found that in Chinese patients with IgA nephropathy, variant rs6677604 was associated with mesangial C3 deposition, and mesangial C3 deposition, but not rs6677604, was associated with IgA nephropat...
Patients with both age-related macular degeneration (AMD) and C3 glomerulonephritis (C3G) are challenged by the absence of effective therapies to reverse and eliminate their disease burden. Capitalizi...
C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely descri...
Three hundred ninety-eight patients with C3 glomerulopathy ( n =296) or Ig-MPGN ( n =102) from a national registry were screened for three complement genes: factor H ( CFH ), factor I ( CFI ), and C3 ...
Fifty-three different rare variants, including 30 (57%), 13 (24%), and ten (19%) in CFH , CFI , and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified a...
In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH , CFI , or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified...
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3....
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating...
Neuroinflammation and autoimmunity are pivotal in the pathogenesis of neurodegenerative diseases. Complement activation and involvement of astrocyte-neuron C3/C3aR pathway have been observed, yet the ...